May 22, 2025 7:00am EDT Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase
May 21, 2025 7:00am EDT Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction
May 14, 2025 7:00am EDT Tonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations
May 12, 2025 4:30pm EDT Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights
Apr 29, 2025 9:05am EDT Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting
Apr 24, 2025 7:55am EDT Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025
Apr 16, 2025 7:00am EDT Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025
Apr 9, 2025 7:00am EDT Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix’s Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana’s Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies
Apr 7, 2025 7:00am EDT Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting
Apr 2, 2025 7:00am EDT Tonix Pharmaceuticals to Present at the 2025 Jones Trading Healthcare and Innovation Conference
